In clinical trials, participants on the highest dose of retatrutide (12mg) lost an average of 28.7% of their body weight, equivalent to roughly 71 pounds for someone starting at the average trial baseline of about 248 pounds. This makes retatrutide the most effective weight loss medication ever studied in clinical trials, surpassing both semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) by a wide margin.

But averages tell only part of the story. The actual amount of weight you could lose on retatrutide depends on your starting weight, the dose prescribed, how long you take the medication, and a range of individual biological factors. Let's break down what the clinical data actually shows.

Weight Loss by Dose Level

The Phase 2 trial of retatrutide tested multiple dose levels over 48 weeks. This gives us a clear picture of how weight loss scales with dosage:

• 1mg weekly: Participants lost an average of 8.7% of body weight. This is comparable to what older weight loss medications achieve.
• 4mg weekly: Average weight loss reached approximately 17.0% of body weight. This is in the range of what semaglutide (Wegovy) produces at its highest dose.
• 8mg weekly: Participants lost an average of 24.3% of body weight. This exceeds what tirzepatide achieves at its highest approved dose.
• 12mg weekly: The highest dose produced the headline number of 28.7% average body weight loss, and notably, the weight loss curve had not yet plateaued at the 48-week mark.

That last point is particularly significant. In most weight loss medication trials, participants reach a plateau somewhere between 36 and 52 weeks. The fact that retatrutide participants were still losing weight at 48 weeks suggests that longer treatment periods could produce even greater results. The Phase 3 TRIUMPH trials, which run for up to 72 weeks, will provide a clearer picture of where that plateau eventually lands.

What Does This Look Like in Real Pounds?

Percentages are useful for clinical comparisons, but most people think about weight loss in pounds or kilograms. Here is what the data translates to for different starting weights at the 12mg dose level:

• Starting at 200 lbs: Average loss of approximately 57 pounds (to about 143 lbs)
• Starting at 250 lbs: Average loss of approximately 72 pounds (to about 178 lbs)
• Starting at 300 lbs: Average loss of approximately 86 pounds (to about 214 lbs)
• Starting at 350 lbs: Average loss of approximately 100 pounds (to about 250 lbs)

These are averages. Some participants in the trial lost more than the average, and some lost less. Individual results varied considerably, which is normal for any medical intervention.

The Range of Individual Results

While the 28.7% average gets the most attention, the distribution of individual results is equally important. In the Phase 2 trial, a substantial percentage of participants on the highest dose lost more than 30% of their body weight. Some participants exceeded 35%. On the other end of the spectrum, a small number of participants lost less than 15%, even on the highest dose.

Several factors influence where an individual falls within this range:

• Starting BMI: Patients with higher starting BMIs tend to lose a larger absolute number of pounds but may lose a smaller percentage of total body weight compared to those with lower starting BMIs.
• Metabolic health: Patients with type 2 diabetes often lose less weight on GLP-1 class medications than those without diabetes. This pattern was also observed with retatrutide, though the difference was less pronounced than with single-agonist drugs.
• Adherence to treatment: Missing doses or not following the titration schedule can significantly reduce weight loss outcomes.
• Diet and activity: While retatrutide produces weight loss even without formal lifestyle changes, participants who also modified their diet and exercise habits tended to lose more.
• Genetics: Individual variation in hormone receptor sensitivity and metabolic rate plays a role that researchers are still working to fully understand.

How Fast Does the Weight Come Off?

Weight loss with retatrutide is not linear. The pattern follows a characteristic curve that most GLP-1 medications share, though at a faster pace.

During the first four to six weeks, weight loss is relatively modest as the dose is gradually titrated upward. Most protocols start at a low dose and increase every two to four weeks to minimize gastrointestinal side effects. During this ramp-up period, participants typically lost 2-4% of body weight.

From weeks 6 through 24, weight loss accelerates significantly. This is the period of most rapid change, with many participants losing 1.5 to 2.5 pounds per week on average. The appetite suppression is most noticeable during this phase, and patients often report dramatic reductions in food cravings and portion sizes.

From weeks 24 through 48 (and likely beyond), the rate of loss begins to slow gradually, though it does not stop entirely. The body is approaching a new equilibrium, and the remaining weight becomes progressively harder to lose as metabolic adaptations take hold.

What Happens When You Stop?

This is the question that often gets overlooked in the excitement about peak weight loss numbers. Data from other GLP-1 medications shows that patients who discontinue treatment tend to regain a significant portion of lost weight. In the STEP 1 extension trial for semaglutide, participants regained about two-thirds of their lost weight within a year of stopping the drug.

Retatrutide-specific discontinuation data from Phase 3 trials is not yet available. However, there is no reason to expect fundamentally different behavior. These drugs work by modifying appetite and metabolism through continuous receptor activation. When that activation stops, appetite and metabolic rate tend to return toward their pre-treatment baseline.

This is why most obesity medicine specialists view these medications as long-term or indefinite treatments, similar to blood pressure or cholesterol medications. The weight loss they produce is real and clinically significant, but maintaining it likely requires ongoing treatment for most patients.

Putting It in Perspective

A 28.7% average weight loss is genuinely unprecedented for a pharmaceutical intervention. To put it in context, that figure approaches the results of Roux-en-Y gastric bypass surgery, which typically produces 25-35% total body weight loss. For the first time, a medication is delivering results in the same neighborhood as major surgery, without the surgical risks, recovery time, or permanent anatomical changes.

That said, retatrutide is still in clinical trials. The Phase 3 results may confirm, exceed, or slightly reduce the Phase 2 numbers. Until those results are published and the drug receives FDA approval, the 28.7% figure should be viewed as promising but preliminary. It is the best data we have, but it is not yet the final word.